The very first patient would receive the first clinical doses of HMBD-001, the first cancer treatment from Hummingbird ...
George Garibaldi and Paolo Zocchi proposed as new independent, non-executive Board membersPatrick Langlois and Luca Benatti ...
Zacks Small Cap Research on MSN
OTC Markets hosts virtual investor presentation with Jim Frakes, CEO and CFO of Aethlon Medical, and M Marin, senior analyst at Zacks SCR
NASDAQ: AEMD Lili Elston: Hello, and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host, Zacks Small Cap Research, we are very pleased you've joined us. The next ...
HotCopper on MSN
The biotech inflection point, and why it’s a 'grand final' for Paradigm Biopharma in CY26
The step from ‘science project’ to commercial asset in the ASX-listed biotechnology landscape is defined by a handful of key ...
First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded ...
The Government of Canada is taking action to streamline access to medicines to save lives, reduce costs, and build our ...
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals ...
ASX-listed healthcare companies are increasingly teaming up with universities to fast-track new therapies, combining academic ...
The finalists for the 2026 Cambridge Independent Science and Technology Awards can now be revealed. Hundreds of nominations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results